CAR-T
19 videos · last 6 months shuffled daily, then older videos newest first
▶
1:41 Emerging Cellular Therapies in Gastrointestinal Cancers
Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, discusses emerging cellular therapies in gastrointestinal (GI) cancer, including an engineered T-cell receptor therapy against p53 which has shown promise in pancreatic cancer and a CAR T-cell therapy targeting CLDN18.2.
▶
4:10 Legend Biotech's Ying Huang on In Vivo CAR-T at EHA 2026
Dr. Ying Huang, CEO of Legend Biotech, discusses first Phase 1 results for LB2501, an investigational in vivo CAR-T therapy in relapsed or refractory B-cell non-Hodgkin lymphoma, presented at EHA 2026, in an OncoDaily interview sponsored by Legend Biotech.
▶
11:35 SOHO 2026 Highlights in Lymphoma, MDS and CLL
Jasmine M. Zain, MD, of Memorial Sloan Kettering, David Sallman, MD, of Moffitt Cancer Center, and Julie M. Vose, MD, of the University of Nebraska Medical Center discuss SOHO 2026 presentations, including phase 2a ofirnoflast results in lower-risk MDS.
▶
19:23 Why Cancer Patients Are Flying to China for Treatment
BBC World Service's Asia Specific examines why a growing number of cancer patients travel to China for CAR-T cell therapy that can be faster, cheaper and more accessible than in many Western countries.
▶
43:43 CAR-T Therapy in Neuroimmune Disease
Dr. Barbara Willekens of the University of Antwerp explains CAR-T cell therapy, why it is being explored in autoimmune disease including emerging trials in NMOSD and MOGAD, and how patients are selected for trials, for SRNA.
▶
2:46 ASCO 2026: CARTITUDE-4 Cytogenetic Subgroup Analysis
Roberto Mina, MD, of Winship Cancer Institute at Emory discusses the CARTITUDE-4 cytogenetic subgroup analysis in relapsed or refractory multiple myeloma.
▶
40:29 Panteli Theocharous on Autoimmune CAR T and Trial Endpoints
Dr. Panteli Theocharous discusses the benefit-risk calculus of autoimmune CAR T compared with oncology, patient burden from conditioning, apheresis and monitoring, and rethinking trial endpoints, on Life Science Connect's Cell & Gene: The Podcast.
▶
18:40 What Is Real-World Evidence Revealing About CAR T Therapy?
Prof Benoit Tessoulin of CHU Nantes discusses what the French DESCAR-T registry shows about CAR T-cell therapy in routine practice, including patient selection, product comparisons and toxicities, on a European Hematology Association podcast.
▶
51:04 Ethical and Strategic Challenges of CAR-T Commercialisation
In a Consilium Scientific seminar, Stephany Saarti examines the strategic, operational and ethical challenges of advanced immuno-oncology therapies such as CAR-T, from evidence generation to reimbursement and access, and introduces the VERITAS framework.
▶
30:58 CAR-T for NMOSD: A Phase 1 Trial
Dr. Michael Levy and Dr. Benjamin Greenberg describe for SRNA an autologous Phase 1 CAR-T study in aquaporin-4-positive NMOSD at Mass General and UT Southwestern, covering eligibility, risks and lessons for neuroimmune research.
▶
4:49 LB2501 In Vivo CAR-T: First-in-Human Data in B-Cell NHL
Ying Huang, PhD, former CEO of Legend Biotech, discusses first-in-human data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T lentiviral vector, in relapsed/refractory B-cell non-Hodgkin lymphoma at EHA 2026, for SOHO Insider.
▶
2:16 Alyssa's Story: A Base-Edited CAR-T Cell Therapy Trial
Great Ormond Street Hospital introduces Alyssa, 13, who received base-edited cell therapy for T-cell acute lymphoblastic leukaemia in a GOSH and University College London clinical trial after other treatments failed, and the research team behind the trial.
▶
4:42 Phase I Trial on Safety and Feasibility of CAR-T in MS
Jeffrey Dunn, MD, Stanford University School of Medicine, Palo Alto, CA, shares findings on the safety and feasibility of CAR T-cell therapy for multiple sclerosis (MS) from a Phase I trial (NCT06138132).
▶
3:04 CAR-T Clinical Trial for One Ottawa Mom
Natasha Kekre, a hematologist and scientist , and an Ottawa Mom discuss how CAR-T clinical trials use immune cells from a patients body to attack cancer and activate the immune system.
▶
1:42:41 CELLECTIS R&D Day 2025 - Replay
Cellectis presents the full Phase 1 data set for lasme-cel in B-ALL and the Phase 2 trial design, at its 2025 R&D Day.
▶
1:38 Key Highlights from the Phase 1 Dose Escalation Study of PRGN-3006 UltraCAR-T Presented At
Dr. David A. Sallman of Moffitt Cancer Center discusses highlights from the Phase 1/1b safety study of PRGN-3006 UltraCAR-T in relapsed or refractory CD33-positive acute myeloid leukemia and higher-risk myelodysplastic syndromes.
▶
59:43 Cellectis on Gene Editing
Cellectis on using synthetic biology with cell and gene therapy against cancer, across seven trials — three wholly owned and four partnered.
▶
2:42 CAR-T Clinical Trials in China
An MD in Beijing, China discusses current clinical trials being conducted in China at the Beijing Lu Daopei hospital, including CAR-T clinical trials.
▶
51:01 Legend Biotech's Alan Bash on Commercializing CAR-T
Alan Bash, President, Carvykti, at Legend Biotech, discusses how Carvykti became a leading CAR-T therapy for multiple myeloma, commercial-scale manufacturing, the Johnson & Johnson partnership and new competitors, on Life Science Connect's Business of Biotech.